Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.

Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG, de Jong S.

Br J Cancer. 2013 Nov 12;109(10):2685-95. doi: 10.1038/bjc.2013.636. Epub 2013 Oct 17.

2.

Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.

Hori T, Kondo T, Kanamori M, Tabuchi Y, Ogawa R, Zhao QL, Ahmed K, Yasuda T, Seki S, Suzuki K, Kimura T.

Cancer Lett. 2010 Jan 1;287(1):98-108. doi: 10.1016/j.canlet.2009.06.002. Epub 2009 Jul 3.

PMID:
19577358
3.
4.

Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.

Park EJ, Choi KS, Yoo YH, Kwon TK.

Anticancer Drugs. 2013 Mar;24(3):260-9. doi: 10.1097/CAD.0b013e32835c0311.

PMID:
23187459
5.

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.

Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G.

Curr Drug Metab. 2007 May;8(4):395-403.

PMID:
17504227
6.

Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.

Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S.

Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10.

7.

Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.

Tseng HY, Jiang CC, Croft A, Tay KH, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD.

Mol Cancer Ther. 2010 Dec;9(12):3363-74. doi: 10.1158/1535-7163.MCT-10-0646.

8.

Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.

Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):543-52. doi: 10.1016/j.ijrobp.2008.06.1902.

PMID:
18793956
9.

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.

Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S.

Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.

10.

Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.

Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, de Jong S.

Int J Cancer. 2006 Apr 15;118(8):1892-900.

11.

TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.

Heijink DM, Jalving M, Oosterhuis D, Sloots IA, Koster R, Hollema H, Kleibeuker JH, Koornstra JJ, de Vries EG, de Jong S.

J Pathol. 2011 Feb;223(3):378-89. doi: 10.1002/path.2797. Epub 2010 Oct 29.

PMID:
21171083
12.

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M.

Blood. 2008 Apr 1;111(7):3742-50. doi: 10.1182/blood-2007-05-091504. Epub 2008 Jan 10.

13.

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.

Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S.

Leukemia. 2009 Nov;23(11):2090-101. doi: 10.1038/leu.2009.171. Epub 2009 Aug 27.

PMID:
19710698
14.

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.

PMID:
17146434
15.

Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.

van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S.

BMC Cancer. 2011 Jan 27;11:39. doi: 10.1186/1471-2407-11-39.

16.

The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.

Drakos E, Atsaves V, Schlette E, Li J, Papanastasi I, Rassidakis GZ, Medeiros LJ.

Leukemia. 2009 Dec;23(12):2290-9. doi: 10.1038/leu.2009.180. Epub 2009 Sep 10.

PMID:
19741726
17.

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.

Cell Death Dis. 2011 Apr 21;2:e148. doi: 10.1038/cddis.2011.33.

18.

The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.

Tse AK, Chow KY, Cao HH, Cheng CY, Kwan HY, Yu H, Zhu GY, Wu YC, Fong WF, Yu ZL.

J Biol Chem. 2013 Oct 11;288(41):29923-33. doi: 10.1074/jbc.M113.483909. Epub 2013 Aug 28.

19.

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.

Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, Sjollema K, Stricher F, Cool RH, Samali A, Serrano L, Quax WJ.

Cell Death Dis. 2010 Oct 21;1:e83. doi: 10.1038/cddis.2010.61.

20.

Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.

Van Geelen CM, Pennarun B, Ek WB, Le PT, Spierings DC, De Vries EG, De Jong S.

Int J Oncol. 2010 Oct;37(4):1031-41.

PMID:
20811726

Supplemental Content

Support Center